Patent · US Active

Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy

US8883808B2 · kind B2 · utility

6Cited by

20References

15Claims

0Family size

Assignee

Janssen Pharmaceutica NA · BE

Inventors

Pascal Bonaventure · San Diego, US
Christine Dugovic · Chicago, US
Curt A. Dvorak · Poway, US
Dale A. Rudolph · San Diego, US
Jonathan Edward Shelton · San Marcos, US

Key dates

Filing date	Oct 18, 2006
Grant date	Nov 11, 2014
Priority date	—
Expiry date	Dec 29, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin reuptake inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.